• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter: propensity score-handle with care. Authors' reply.

作者信息

Townsend Tristan, Subramanian Sreedhar

机构信息

Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK.

出版信息

Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.

DOI:10.1111/apt.16211
PMID:33368518
Abstract
摘要

相似文献

1
Letter: propensity score-handle with care. Authors' reply.
Aliment Pharmacol Ther. 2021 Jan;53(2):362-363. doi: 10.1111/apt.16211.
2
Letter: propensity score-handle with care.信函：倾向评分——谨慎处理。
Aliment Pharmacol Ther. 2021 Jan;53(2):360-361. doi: 10.1111/apt.16179.
3
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):563-564. doi: 10.1111/apt.15888.
4
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1255-1256. doi: 10.1111/apt.16062.
5
Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
Aliment Pharmacol Ther. 2020 Aug;52(4):753-754. doi: 10.1111/apt.15959.
6
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.信函：在抗TNF难治性克罗恩病中选择优特克单抗和维多珠单抗——细节决定成败。
Aliment Pharmacol Ther. 2020 Aug;52(3):561-562. doi: 10.1111/apt.15862.
7
Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.社论：优特克单抗在305例克罗恩病患者中的真实世界短期疗效——来自ENEIDA注册研究的结果。作者回复
Aliment Pharmacol Ther. 2019 Sep;50(5):600-601. doi: 10.1111/apt.15447.
8
Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.信件：优特克单抗与维多珠单抗作为克罗恩病二线治疗药物的真实世界比较中的潜在选择偏倚——作者回复
Aliment Pharmacol Ther. 2022 Apr;55(8):1070-1071. doi: 10.1111/apt.16896.
9
Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.信函：克罗恩病的免疫抑制治疗应从阿达木单抗开始吗？作者回复。
Aliment Pharmacol Ther. 2013 Apr;37(7):752-3. doi: 10.1111/apt.12245.
10
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
Aliment Pharmacol Ther. 2020 Oct;52(7):1253-1254. doi: 10.1111/apt.16009.